Literature DB >> 15936850

Conversion of MCI to dementia: Role of proton magnetic resonance spectroscopy.

Antonio Metastasio1, Patrizia Rinaldi, Roberto Tarducci, Elena Mariani, Filippo T Feliziani, Antonio Cherubini, Gian Piero Pelliccioli, Gianni Gobbi, Umberto Senin, Patrizia Mecocci.   

Abstract

Mild cognitive impairment (MCI) represents a heterogeneous group of cognitive disturbances at high risk of dementia. The amnestic subtype (aMCI) might be a prodromal state of Alzheimer's disease (AD). The aim of this study is the identification, by proton magnetic resonance spectroscopy (1H MRS), of modifications in brain metabolites able to detect subjects with aMCI at risk of conversion towards AD. Twenty-five subjects with aMCI and 29 normal elderly were enrolled; they underwent a comprehensive clinical and instrumental assessment, a cerebral 1H MRS scan to measure N-acetyl aspartate (NAA), choline (Cho), myo-inositol (mI) and creatine (Cr) in the paratrigonal white matter, bilaterally. After 1 year, 5 MCI subjects became demented (progressive MCI, pMCI). Their baseline levels of metabolites were compared with those evaluated in stable MCI (sMCI) and in controls. We observed a significant difference of the NAA/Cr ratio between pMCI (1.48+/-0.08) and sMCI (1.65+/-0.12) and between pMCI and controls (1.63+/-0.16) in the left hemisphere, suggesting that this metabolic alteration can be detected before the clinical appearance of dementia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15936850     DOI: 10.1016/j.neurobiolaging.2005.05.002

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  33 in total

1.  [MR spectroscopy in dementia].

Authors:  T Hauser; L Gerigk; F Giesel; L Schuster; M Essig
Journal:  Radiologe       Date:  2010-09       Impact factor: 0.635

Review 2.  The application of NMR-based metabonomics in neurological disorders.

Authors:  Elaine Holmes; Tsz M Tsang; Sarah J Tabrizi
Journal:  NeuroRx       Date:  2006-07

Review 3.  Recent advances in magnetic resonance neurospectroscopy.

Authors:  Yael Rosen; Robert E Lenkinski
Journal:  Neurotherapeutics       Date:  2007-07       Impact factor: 7.620

4.  [Mild cognitive impairment: diagnostic value of different MR techniques].

Authors:  T Hauser; P A Thomann; B Stieltjes; M Essig
Journal:  Radiologe       Date:  2011-04       Impact factor: 0.635

5.  Decreased Glutamate Levels in Patients with Amnestic Mild Cognitive Impairment: An sLASER Proton MR Spectroscopy and PiB-PET Study.

Authors:  Burcu Zeydan; Dinesh K Deelchand; Nirubol Tosakulwong; Timothy G Lesnick; Orhun H Kantarci; Mary M Machulda; David S Knopman; Val J Lowe; Clifford R Jack; Ronald C Petersen; Gülin Öz; Kejal Kantarci
Journal:  J Neuroimaging       Date:  2017-06-29       Impact factor: 2.486

6.  Alzheimer disease: postmortem neuropathologic correlates of antemortem 1H MR spectroscopy metabolite measurements.

Authors:  Kejal Kantarci; David S Knopman; Dennis W Dickson; Joseph E Parisi; Jennifer L Whitwell; Stephen D Weigand; Keith A Josephs; Bradley F Boeve; Ronald C Petersen; Clifford R Jack
Journal:  Radiology       Date:  2008-07       Impact factor: 11.105

7.  1H MRS spectroscopy in preclinical autosomal dominant Alzheimer disease.

Authors:  Elizabeth Joe; Luis D Medina; John M Ringman; Joseph O'Neill
Journal:  Brain Imaging Behav       Date:  2019-08       Impact factor: 3.978

Review 8.  Proton MRS in mild cognitive impairment.

Authors:  Kejal Kantarci
Journal:  J Magn Reson Imaging       Date:  2013-04       Impact factor: 4.813

9.  MR spectroscopy of cerebral white matter in type 2 diabetes; no association with clinical variables and cognitive performance.

Authors:  Audrey Tiehuis; Femke van der Meer; Willem Mali; Marc Pleizier; Geert Jan Biessels; Jaap Kappelle; Peter Luijten
Journal:  Neuroradiology       Date:  2009-09-30       Impact factor: 2.804

10.  Beyond mild cognitive impairment: vascular cognitive impairment, no dementia (VCIND).

Authors:  Blossom Cm Stephan; Fiona E Matthews; Kay-Tee Khaw; Carole Dufouil; Carol Brayne
Journal:  Alzheimers Res Ther       Date:  2009-07-09       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.